このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Medpace Holdings マネジメント

マネジメント基準チェック /44

Medpace Holdings'の CEO はAugust Troendleで、 Jul1992年に任命され、の在任期間は 31.92年です。の年間総報酬は$ 1.65Mで、 49.5%給与と50.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の17.43%を直接所有しており、その価値は€ 2.02B 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と5.8年です。

主要情報

August Troendle

最高経営責任者

US$1.6m

報酬総額

CEO給与比率	49.5%
CEO在任期間	31.9yrs
CEOの所有権	17.4%
経営陣の平均在職期間	5.3yrs
取締役会の平均在任期間	5.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Medpace Holdings の収益と比較して、August Troendle の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	US$312m
Dec 31 2023	US$2m	US$814k	US$283m
Sep 30 2023	n/a	n/a	US$273m
Jun 30 2023	n/a	n/a	US$268m
Mar 31 2023	n/a	n/a	US$257m
Dec 31 2022	US$2m	US$770k	US$245m
Sep 30 2022	n/a	n/a	US$227m
Jun 30 2022	n/a	n/a	US$209m
Mar 31 2022	n/a	n/a	US$199m
Dec 31 2021	US$6m	US$697k	US$181m
Sep 30 2021	n/a	n/a	US$182m
Jun 30 2021	n/a	n/a	US$175m
Mar 31 2021	n/a	n/a	US$159m
Dec 31 2020	US$4m	US$608k	US$145m
Sep 30 2020	n/a	n/a	US$124m
Jun 30 2020	n/a	n/a	US$107m
Mar 31 2020	n/a	n/a	US$110m
Dec 31 2019	US$8m	US$504k	US$100m
Sep 30 2019	n/a	n/a	US$93m
Jun 30 2019	n/a	n/a	US$88m
Mar 31 2019	n/a	n/a	US$78m
Dec 31 2018	US$528k	US$420k	US$73m
Sep 30 2018	n/a	n/a	US$61m
Jun 30 2018	n/a	n/a	US$52m
Mar 31 2018	n/a	n/a	US$45m
Dec 31 2017	US$598k	US$419k	US$39m

報酬と市場: Augustの総報酬 ($USD 1.65M ) は、 German市場 ($USD 5.00M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Augustの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

August Troendle (68 yo)

31.9yrs

在職期間

US$1,646,031

報酬

Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
August Troendle	Chairman & CEO	31.9yrs	US$1.65m	17.43% $ 2.0b
Jesse Geiger	President	2.8yrs	US$945.08k	0.070% $ 8.1m
Kevin Brady	CFO & Treasurer	5.3yrs	US$690.48k	0.019% $ 2.3m
Susan Burwig	Executive Vice President of Operations	7.4yrs	US$1.12m	0.024% $ 2.8m
Stephen Ewald	Chief Compliance Officer	12yrs	US$914.64k	0.043% $ 5.1m
Brandon Ebken	Chief Information Officer	3.4yrs	データなし	データなし
Lauren Morris	Associate Director of Investors Relations	no data	データなし	データなし
Todd Meyers	Vice President of Business Development & Marketing	no data	データなし	データなし
John Wynne	Senior Vice President of Commercial Operations & Clinical Pharmacology Unit	no data	データなし	データなし
Reinilde Heyrman	Chief Medical Officer of Medical Department	1.4yrs	データなし	データなし
Gina Leisring	Senior Vice President of Clinical Monitoring	no data	データなし	データなし

5.3yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: 01Pの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
August Troendle	Chairman & CEO	31.9yrs	US$1.65m	17.43% $ 2.0b
Fred Davenport	Lead Independent Director	5.8yrs	US$264.98k	0.0065% $ 757.5k
Cornelius McCarthy	Independent Director	5.8yrs	US$217.48k	0.017% $ 1.9m
Robert Kraft	Independent Director	7.9yrs	US$227.35k	0.0014% $ 169.8k
Brian Carley	Independent Director	7.9yrs	US$234.97k	0.070% $ 8.2m
Femida Gwadry-Sridhar	Independent Director	1.4yrs	US$258.37k	0% $ 0
Ashley Keating	Independent Director	5.1yrs	US$209.98k	0.00081% $ 94.8k

5.8yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: 01Pの取締役会は経験豊富であると考えられます ( 5.8年の平均在任期間)。

Medpace Holdings マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Executive Vice President of Operations recently sold €2.8m worth of stock

Chairman & CEO recently sold €3.5m worth of stock

Chairman & CEO recently sold €6.3m worth of stock

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Chairman & CEO recently sold €23m worth of stock

Executive Vice President of Operations recently sold €3.5m worth of stock

Recent updates

Medpace Holdings, Inc. to Report Q2, 2024 Results on Jul 22, 2024

Executive Vice President of Operations recently sold €2.8m worth of stock

Chairman & CEO recently sold €3.5m worth of stock

Chairman & CEO recently sold €6.3m worth of stock

New minor risk - Share price stability

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$3.33 (vs US$2.35 in 1Q 2023)

Medpace Holdings, Inc., Annual General Meeting, May 17, 2024

Medpace Holdings, Inc. to Report Q1, 2024 Results on Apr 22, 2024

Chairman & CEO recently sold €23m worth of stock

Investor sentiment improves as stock rises 18%

Full year 2023 earnings released: EPS: US$9.21 (vs US$7.57 in FY 2022)

Executive Vice President of Operations recently sold €3.5m worth of stock

Now 21% undervalued

Chairman & CEO recently sold €20m worth of stock

Medpace Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2023 and 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$2.30 (vs US$2.13 in 3Q 2022)

Medpace Holdings, Inc. to Report Q3, 2023 Results on Oct 23, 2023

Now 20% undervalued

Second quarter 2023 earnings released: EPS: US$2.00 (vs US$1.52 in 2Q 2022)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2023

Medpace Holdings, Inc. to Report Q2, 2023 Results on Jul 24, 2023

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Growth-Defensive Index

Now 21% undervalued

First quarter 2023 earnings released: EPS: US$2.35 (vs US$1.76 in 1Q 2022)

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: EPS: US$7.58 (vs US$5.06 in FY 2021)

Medpace Holdings, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Medpace Holdings, Inc. Announces Resignation of Thomas C. King to Board

CFO & Treasurer recently sold €440k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$2.13 (vs US$1.35 in 3Q 2021)

Medpace Holdings, Inc. (NasdaqGS:MEDP) announces an Equity Buyback for $500 million worth of its shares.

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2022 and 2023

Medpace Holdings, Inc. to Report Q3, 2022 Results on Oct 24, 2022

Chairman & CEO recently bought €15m worth of stock

Chairman & CEO recently bought €10m worth of stock

Second quarter 2022 earnings released: EPS: US$1.52 (vs US$1.11 in 2Q 2021)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Medpace Holdings, Inc. to Report Q2, 2022 Results on Jul 25, 2022

Insufficient new directors

First quarter 2022 earnings released: EPS: US$1.76 (vs US$1.21 in 1Q 2021)

Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2022

Medpace Holdings, Inc., Annual General Meeting, May 20, 2022

Investor sentiment improved over the past week

Lead Independent Director recently bought €64k worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medpace Holdings, Inc. Provides Consolidated Earnings Guidance for the Year 2022

Now 22% undervalued after recent price drop

Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS US$1.11 (vs US$0.68 in 2Q 2020)

First quarter 2021 earnings released: EPS US$1.21 (vs US$0.80 in 1Q 2020)

Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2021

Medpace Holdings, Inc. to Report Q1, 2021 Results on Apr 26, 2021

Executive Vice President of Operations recently sold €859k worth of stock

Full year 2020 earnings released: EPS US$4.07 (vs US$2.79 in FY 2019)

Revenue beats expectations

New 90-day high: €121

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from Russell 2000 Dynamic Index

Medpace Holdings, Inc. to Report Q4, 2020 Results on Feb 15, 2021

New 90-day high: €109

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

Medpace Holdings, Inc.(NasdaqGS:MEDP) dropped from S&P 600 Health Care (Sector)

Medpace Holdings, Inc. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day high - €110

New 90-day high - €102

マネジメント基準チェック /44